What is the difference between accretion and value creation?

Accretion is an EPS metric (accounting-based). Value creation is economic (DCF-based). A deal can be dilutive on EPS but create shareholder value if it generates a return above WACC. Conversely, a deal can be accretive on EPS but destroy value if synergies are overestimated or integration costs are underestimated. The best deals are both accretive and create economic value.

What is a typical accretion/dilution range at close?

Industrial deals are often 0-5% dilutive at close due to high purchase multiples. Strategic deals with identifiable synergies are often 2-5% accretive in Year 1. Deals announced as "accretive" typically mean accretive in Year 2-3 with synergies, not Year 1. If a deal is >10% dilutive, it requires very large synergies to justify.

How do you handle earnouts in the merger model?

Earnouts are contingent payments. Model the base purchase price separately from the earnout. The earnout triggers if the target hits certain metrics (revenue, EBITDA) in Years 1-3. If you're conservative, assume only 50-70% of the earnout is paid. This reduces the effective price and improves accretion, but introduces risk if targets are missed.

What is pro-forma and pro-forma-adjusted?

Pro-forma = combined statutory results (as if the merger happened at the start of the period). Pro-forma-adjusted = adjusted for one-time deal costs and synergies. Boards prefer pro-forma-adjusted because it shows the "run-rate" economics post-integration, not the messy Year 1 with integration costs.

How does leverage affect post-deal EPS?

Higher debt means higher interest expense, which reduces earnings and EPS. A leveraged deal (financed with debt) will be more dilutive on EPS than an all-stock deal. However, debt is cheaper than equity (due to the tax shield), so moderate leverage is optimal. Too much leverage reduces flexibility and increases refinancing risk.

What metrics do boards care about in M&A?

Year 1 and Year 3 accretion/dilution, IRR (looking forward, expected return on the deal), pro-forma leverage (is it acceptable?), run-rate synergies, and synergy confidence (what could go wrong?). Boards also scrutinise the seller's track record on M&A — if past deals destroyed value, they're sceptical.

Technical Interview Guide

Merger Model & Accretion-Dilution Analysis Interview Questions & Walkthrough

Step-by-step explanation, real interview questions, model answers at different levels, and AI-scored practice.

Quick answer

A merger model projects the pro-forma combined company post-acquisition and calculates the impact on the acquirer's earnings per share (EPS). Accretion occurs when the combined company's EPS increases relative to standalone; dilution occurs when it decreases. Key drivers: deal price, financing structure, synergies, and combined earnings.

Step 1

What is a merger model and why do deals sometimes dilute EPS?

A merger model combines two companies' financial statements and projects pro-forma results. The acquirer pays a price (premium) for the target. If that price is high relative to the target's earnings, the combined company's EPS might decrease (dilution), even if the deal creates value. The opposite is accretion. M&A textbooks spend little time here, but bankers spend 80% of their time on merger models.

Consider a simple example: Acquirer has £1bn market cap, 100m shares (£10/share), 8% EBIT margin on £2bn revenue = £160m EBIT. Earnings = £120m (20% tax). Acquirer wants to buy Target for £500m. Target has £500m revenue, same 8% EBIT margin = £40m EBIT, £30m earnings. If Acquirer issues £500m of stock at £10/share (50m new shares), combined company has 150m shares and £150m earnings = £1.00 EPS (diluted from £1.20 standalone). This is accretive only if the deal generates enough synergies.

The point: paying a high price can instantly dilute EPS, even for a strategically sound deal. Bankers model this extensively because boards and investors scrutinise accretion/dilution. A highly dilutive deal needs strong synergies to justify it; an immediately accretive deal is easier to sell.

Step 2

Step 1 — Set up the purchase accounting and bridge

Start with the purchase price and determine how it's financed. If Acquirer buys Target for £500m using £200m cash, £200m debt, and £100m stock (at £10/share = 10m shares), record the impacts. Cash decreases by £200m. Debt increases by £200m. Shares outstanding increase by 10m. On the balance sheet, create goodwill to reflect the premium paid over Target's book value.

Calculate Acquirer's standalone EPS as the baseline. Then add Target's standalone earnings and any transaction costs (one-time fees, contingent consideration). The result is combined pro-forma earnings. Divide by pro-forma shares outstanding to get combined EPS.

Key calculations: Standalone Acquirer EPS = Acquirer Earnings / Acquirer Shares. Standalone Target EPS = Target Earnings / Target Shares (annualised). Combined EPS (Year 1, pre-synergies) = (Acquirer Earnings + Target Earnings) / (Acquirer Shares + New Shares Issued). This is the starting point before synergies.

Step 3

Step 2 — Model synergies and pro-forma earnings

Synergies are the economic value created by combining two businesses. Cost synergies (£50-100m annually): elimination of duplicate functions (CFO offices, IT departments), consolidation of suppliers, reduction of overhead. Revenue synergies (£20-50m): cross-selling, new markets, pricing improvements. Model these conservatively — say 50-70% of identified synergies actually materialise.

Example: £200m in identified cost synergies, assume 60% realisation = £120m annual savings. These flow through EBIT. Post-tax impact: £120m × (1 - 20% tax) = £96m of annual earnings. If combined company has 150m shares, synergies add £0.64 EPS. If deal was initially dilutive by £0.10/share, synergies make it accretive by £0.54/share.

Model synergies by year. Year 1 might realise 30-40% (integration is underway), Year 2 40-60%, Year 3+ full run-rate. Conservative approach is critical — overestimated synergies are a primary reason M&A destroys value. Always show sensitivity: base case (70% realisation), upside case (85%), downside case (50%).

Step 4

Step 3 — Calculate accretion/dilution and pro-forma multiples

Accretion/Dilution % = (Combined EPS - Acquirer Standalone EPS) / Acquirer Standalone EPS. If Acquirer standalone EPS is £1.20 and combined (pre-synergies) EPS is £1.10, dilution is (£1.10 - £1.20) / £1.20 = -8.3%. If combined EPS (with synergies) is £1.50, accretion is (£1.50 - £1.20) / £1.20 = +25%. Banks often report accretion assuming full synergies realised immediately — unrealistic but politically convenient.

Also calculate pro-forma valuation multiples: Combined EV/EBITDA, Combined P/E. If the deal is at 10x EBITDA but combined company trades at 9x due to integration costs or worse margins, that's a red flag. Compare to peer multiples.

Create a sensitivity table showing accretion/dilution across different synergy assumptions and purchase price levels. This shows how deal outcomes change with key variables. Boards love seeing this — it frames downside and upside.

Step 5

Step 4 — Key levers and deal structure

All-cash deals are immediately dilutive on EPS (no new shares issued, but purchase price reduces available equity capital). All-stock deals dilute shares outstanding (large issuance). Hybrid deals (cash + stock + debt) balance the impact. Earnouts (payment contingent on future performance) reduce immediate dilution but add complexity.

Purchase price is the primary lever. A lower price (more accretive). Financing structure matters: equity financing dilutes shares (accretive on earnings, dilutive on shares); debt financing is cheaper but increases leverage. The optimal structure balances EPS accretion with financial ratios (leverage, interest coverage).

Integration assumptions matter. Will margins compress or expand post-deal? What's the revenue retention rate? Will the company need integration costs (severance, systems, facilities)? These flow through to pro-forma earnings and impact accretion/dilution. Model conservatively.

Questions

Merger Model & Accretion-Dilution Analysis interview questions

1What is a merger model and how do you build one?
2Explain accretion and dilution.
3How do you calculate standalone and pro-forma EPS?
4What are synergies and how do you model them?
5Walk me through the accretion/dilution calculation.
6Why might an immediately dilutive deal still be strategically smart?
7How does the financing structure (cash vs stock vs debt) affect EPS impact?
8What is purchase accounting and how does it affect the balance sheet?
9Calculate combined EPS given: Acquirer EPS £2.00, shares 100m, Target EPS £0.80, shares 50m, Acquirer issues 20m shares at £20/share.
10How would you model synergies and what assumptions would you stress?
11What is the relationship between the price paid and accretion/dilution?
12How do earnouts affect the deal model?
13What happens to WACC post-deal?
14How would you present accretion/dilution to a client board?

Model answers

Example answers at different levels

Click a level to see the expected answer depth.

Question

Explain accretion and dilution.

Answer

Accretion is when combining two companies increases EPS relative to the acquirer's standalone EPS. Dilution is when it decreases. If the acquirer has £2.00 EPS and the combined company has £1.90 EPS, that's dilution. The reason is usually that the acquirer paid a high price for the target relative to its earnings. Dilution can be offset by synergies — if the combination generates cost savings or revenue improvements, earnings increase and dilution goes away. Most deals are initially dilutive but become accretive as synergies are realised.

Intervyo Learn

Master Merger Model & Accretion-Dilution Analysis inside out

Intervyo Learn offers 12 structured courses covering every technical topic you'll face in interviews. Merger Model & Accretion-Dilution Analysis is covered in depth in the Investment Banking course — from fundamentals to the follow-up questions that trip up most candidates.

Explore Intervyo Learn

Free for 3 days · No card charged until trial ends · Cancel anytime

Follow-ups

Common follow-up questions

If the target's EBITDA margin is lower than the acquirer's, what does that mean for accretion?

How would you model an earnout where payment is contingent on future EBITDA?

Calculate combined EPS: Acquirer £100m earnings on 100m shares, Target £30m earnings on 50m shares, Acquirer pays £500m using 40m new shares.

What is the relationship between the purchase multiple paid and accretion/dilution?

If synergies don't materialise, what's the downside accretion/dilution?

How would a change in combined company leverage affect WACC and valuation?

What is the value of synergies and how do you calculate it?

Avoid

Common mistakes on merger model & accretion-dilution analysis questions

Assuming 100% synergy realisation immediately. Synergies ramp over 2-3 years. Model conservatively — assume 50-70% realisation by Year 3.

Forgetting to include all sources and uses of funds. Cash used, debt raised, stock issued must balance. If they don't, something is wrong in the model.

Not adjusting shares for stock issuance. If the acquirer issues 30m shares to finance the deal, combined shares increase by 30m. Forgetting this understates dilution.

Ignoring integration costs. One-time costs (severance, systems, facilities) reduce Year 1 earnings. Model these explicitly.

Overestimating revenue synergies. Cost synergies are easier to achieve than revenue synergies. Conservative boards assume zero revenue synergies and require high conviction for any.

Mixing pre- and post-tax synergy numbers. Synergies flow through as EBITDA savings. Convert to after-tax earnings impact before adding to the model.

Firms

Which firms ask merger model & accretion-dilution analysis questions?

Goldman Sachs

Merger model mastery expected. Tested across M&A teams. Emphasis on build-from-scratch models.

Morgan Stanley

Core daily skill for M&A bankers. Models tested in interviews and on the job.

JP Morgan

Merger models used extensively. Expected to build quickly and adapt to real deal scenarios.

Lazard

Advanced merger model variants. Earnouts, contingent consideration, complex structures tested.

Evercore

Models must be robust and stress-tested. Sensitivity analysis and scenario variance required.

Centerview Partners

Known for rigorous models. Expected to build and present merger models in interviews.

FAQ

Merger Model & Accretion-Dilution Analysis FAQs

Master every technical topic

AI-scored practice across DCF, LBO, valuation, M&A, and 16 more technical topics. Firm-specific questions with detailed feedback.

Start free trial

Free for 3 days · No card charged until trial ends · Cancel anytime